Feb 9, 2022
VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher’s screen for angel-scale biotech? Listen and find out.
Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson
Highlights:
- Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph
- A New Way to Deliver Drugs Orally
- How VeraMorph Gets Around the Solubility Problem
- VeraMorph’s Approach Is Janus-like: Shelf Stable but Available Where Needed
- The Decade of Biotech & VeraMorph
- AltrixBio: Gastric Bypass Surgery in a Pill
- Sal Daher’s Biotech Screen: Strong Patents
- “VeraMorph actually owns the patents outright for this platform technology.”
- “We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery...”
- Sal Daher’s Biotech Screen: Capable Academic Founder
- Sal Daher’s Biotech Screen: Is it Angel-Scale?
- US$1 Million Will Get VeraMorph to Production for Pre-Clinical Trials
- “...chances of reaching that next set of milestones is 90% or above.”
- Doug Godfrin Is Collaborating with Colin Minchom, PhD, a Veteran of Drug Development
- US$ 2 to 3 million More Will Take VeraMorph to Clinical Stage, Doug Predicts
- Sal and Doug Look at the Odds of Getting to Clinical Stage
- Sal Daher’s Biotech Screen: Do Strategics Care?
- Sal Daher’s Biotech Screen: Platform Technology?
- Sponsors Purdue University and Peter Fasse Are Founder-Friendly
- The Upside of Failure in Biotech
- This guy calls me up, "Saleh, let's get together at Darwin's in Cambridge. I want to talk to you about a new company."
- Doug Godfrin’s Parting Thoughts
Topics: biotech